- [PRESSWIRE] GRENOBLE, France – 17 Juillet, 2026 — Diabeloop, entreprise pionnière dans l’intelligence artificielle thérapeutique pour la gestion du diabète, annonce aujourd’hui une avancée majeure et dès maintenant disponible pour les utilisateurs de son système de délivrance automatisée d’insuline DBLG1 : la possibilité de synchroniser désormais leurs données avec la plateforme de télésurveillance du diabète Glooko XT®. Cette intégration stratégique a pour objectif d’offrir aux professionnels de santé et aux patients un suivi fluide et optimal, spécifiquement pensé pour s’intégrer dans les parcours de soins.
- [PRESSWIRE] SEJONG, KOREA – July 14, 2026 — Azcuris Co., Ltd. announced that it has entered into a research collaboration agreement with AstraZeneca, a leading global biopharmaceutical company, to discover innovative therapies for respiratory and Th2-driven diseases. The collaboration was announced at the NOVA Global Connect 2026 event held in San Diego, California.
- [PRESSWIRE] GRENOBLE, France – July 10, 2026 – Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 Automated Insulin Delivery (AID) system, fully integrated with ViCentra’s Kaleido insulin patch pump and Dexcom G7 Continuous Glucose Monitoring (CGM), is now officially open for prescription in Germany (and the Netherlands later this summer).
- Students for Sensible Drug Policy (SSDP) urges the public to speak out before July 31 using its federal comment tool as the government moves to criminalize 7-hydroxymitragynine (7-OH) above a proposed threshold while advancing broader emergency Schedule I actions against promising opioid research compounds.
- Diabeloop, a pioneer in therapeutic AI, today announced the launch of a new, highly anticipated tool: the DBLG2 Demo App. Designed to make the future of diabetes management accessible to everyone, the DBLG2 Demo app is an interactive simulation and a preview of the virtual DBLG2 System.
- Funding Co-Led by a National Healthcare Insurance Company and AlleyCorp, with participation from Health Velocity Capital Investment accelerates technology-enabled, community-centered care model
- Veterans, Clinicians, Researchers, and Community Leaders Launch Carolinas for Care to Expand Safe, Evidence-Based Access to Psychedelic-Assisted Therapies Across North and South Carolina
- EBME Expo 2026 is less than a month away and promises to be the largest edition yet with more than 200 exhibitors taking part. Businesses are coming from across the UK, Europe, Asia and North America, including Turkiye, Germany, US, Italy, Pakistan, Holland and India, and a special feature will be a pavilion showcasing med-tech manufacturers and suppliers from China.
- Leadership transition reflects Company’s growth, operational maturity, and commitment to scaling recovery-oriented care for people living with serious mental illness…
- Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announced technical readiness, CE marking approval and the gradual European launch of its latest Automated Insulin Delivery (AID) system, DBLG2, integrated with Dexcom G7 Continuous Glucose Monitoring (CGM) system.
- [PRESSWIRE] DENMARK – 30 April, 2026 — °MEQU today announced that its °M Station has received clearance from the U.S. Food and Drug Administration, marking a major step forward in trauma care by enabling uninterrupted blood and IV fluid warming from the point of injury through hospital treatment.
- [PRESSWIRE] Monaco – 30 March, 2026 — EMA Aesthetics (www.emaaesthetics.com), a global aesthetics company focused on regenerative innovation, today announced the scientific unveiling of BLŪPRIN™, its human exosome platform. This unveiling builds on EMA Aesthetics’s previously announced strategic relationship with MonoTx™, reinforcing a shared commitment to advancing next-generation regenerative innovation.
- [PRESSWIRE] 爱尔兰都柏林 —— 2026年3月11日 —— 总部位于都柏林的全球美学公司 EMA Aesthetics（www.emaaesthetics.com）宣布对 MonoTx Global Holdings, Inc.（MonoTx） 进行战略投资。此次投资将加强双方在下一代再生医学美容领域的合作，并为长期创新发展奠定更坚实的基础。
- 【PRESSWIRE】愛爾蘭都柏林 – 2026年3月11日 – 全球美學公司 EMA Aesthetics（www.emaaesthetics.com）欣然宣佈對 MonoTx Global Holdings, Inc.（「MonoTx」）進行策略性投資，進一步加強雙方於次世代再生美學領域的合作，並為長期創新奠定穩固基礎。
- [PRESSWIRE] Dublin, Ireland – 11th March, 2026 – EMA Aesthetics (www.emaaesthetics.com), a global aesthetics company headquartered in Dublin, is pleased to announce a strategic investment in MonoTx Global Holdings, Inc. (“MonoTx”), strengthening the companies’ collaboration in next-generation regenerative aesthetics and expanding the foundation for long-term innovation.
- [PRESSWIRE] FRANCE – 18 February, 2026 — Théa, an independent pharmaceutical group dedicated exclusively to eye care, announces the development of a structured roadmap to reduce its greenhouse gas emissions, in alignment with international climate objectives and the global ambition of carbon neutrality by 2045.
- [PRESSWIRE] Dar es Salaam, Tanzania – 10th February, 2026 – 10 February, 2026 — Tanzania has made significant strides in reducing the risk of epilepsy-related deaths, with the national mortality rate dropping from six percent to four percent in recent years.
- [PRESSWIRE] London, UK – 9 February, 2026 — Optimed Ltd, today announced a strategic partnership with I-Clarity to integrate Optimed’s innovative ReferAI solution into the I-Clarity’s optometry practice management software. ReferAI vastly speeds up the referral workflow and enhances 2-way communication with ophthalmology.
- [PRESSWIRE] DODOMA, Tanzania — 24th January, 2026 — Tanzania has begun rolling out a nationwide universal health insurance programme, joining a growing number of African countries seeking to expand access to healthcare through state-backed systems.
- [PRESSWIRE] Grenoble, France — January 21, 2026 — Diabeloop, a pioneer in therapeutic artificial intelligence, announces that its DBLG2 AID has become the first solution cleared by both the U.S. Food and Drug Administration (FDA) and the CE Mark where meal announcements are no longer mandatory. Although not announcing meals might lead to a lower glycemic control, this offers choice to the patients in managing diabetes in their everyday life. This marks a major step forward in the evolution of automated insulin delivery and a meaningful milestone toward a fully closed-loop system.
- Companies anticipate product readiness by end of 2026 and launch in the US in 2027. Integration will give people with diabetes more choice in how they manage their diabetes care with twiist.
- Diabeloop receives FDA 510(k) clearance for DBLG2, an Automated Insulin Delivery algorithm in an App: a strategic turning point. The company confirms its status as a global reference partner for automated insulin delivery, with the validation of its DBLG2 algorithm and its predetermined Change Control Plan (PCCP) by the FDA.
- [PRESSWIRE] STOCKHOLM – Dec. 18, 2025 — Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held in person in Stockholm, Sweden, on 18 February 2026, starting at 13:00 CET. A live webcast will also be available for remote participants.
- [PRESSWIRE] Geneva – October 20, 2025 – SGS, the world’s leading testing, inspection and certification company, has unveiled ‘SGS DIGITAL TRUST: Across technologies, services and organizations’ a new global framework that unites its digital trust services into one structured and consistent approach.
- [PRESSWIRE] CAMBRIDGE, Mass., Sept. 16, 2025 — Flagship Pioneering, a scientific innovation engine for platforms and products, and Vesalius Therapeutics, a company pioneering a revolutionary platform to redefine common diseases for breakthroughs in treatments, targets and clinical trials, today announced the appointment of Yasir Al-Wakeel, BM BCh (Doctor of Medicine and Surgery), as CEO-Partner of Flagship and CEO of Vesalius. He succeeds John Mendlein, Executive Partner at Flagship Pioneering, who has served as interim CEO and will continue in his role as Executive Chairman.
- [PRESSWIRE] Schenectady, NY – 22 August, 2025 — Utech Products Inc., the parent company of EndoSoft, LLC., which is a leader in advanced AI-driven medical software, announced today that the European Patent office (EPO) has issued European Patent No. EP 3 930 610 B1, titled “AI Systems for Detecting and Sizing Lesions.”
- [PRESSWIRE] Melbourne, Australia – July 10, 2025 — As mental health services around the world grapple with rising demand and limited access, a new 2025 study points to a powerful digital solution for people living with posttraumatic stress disorder (PTSD)- especially those unable to access regular therapy.
- Diabeloop announces Commercial Availability of DBLG1 with Dana-i Insulin Pump in Germany.
- [PRESSWIRE] ANDERNACH, Germany and MONTREAL – June 25, 2025 — LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality and cost-competitive large-scale manufacturing capacities.
- [PRESSWIRE] London, UK – 27 May, 2025 — With only a few weeks to go, pre-registration is building fast for EBME Expo 2025, the UK’s leading healthcare technology exhibition and conference series.